791834-45-2Relevant academic research and scientific papers
AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES
-
Paragraph 0132, (2015/12/18)
The present invention provides a compound of Formula (I) or Formula (II): enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula (I) and (II) are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer
Yao, Wenqing,Zhuo, Jincong,Burns, David M.,Xu, Meizhong,Zhang, Colin,Li, Yun-Long,Qian, Ding-Quan,He, Chunhong,Weng, Lingkai,Shi, Eric,Lin, Qiyan,Agrios, Costas,Burn, Timothy C.,Caulder, Eian,Covington, Maryanne B.,Fridman, Jordan S.,Friedman, Steven,Katiyar, Kamna,Hollis, Gregory,Li, Yanlong,Liu, Changnian,Liu, Xiangdong,Marando, Cindy A.,Newton, Robert,Pan, Max,Scherle, Peggy,Taylor, Nancy,Vaddi, Kris,Wasserman, Zelda R.,Wynn, Richard,Yeleswaram, Swamy,Jalluri, Ravi,Bower, Michael,Zhou, Bing-Bing,Metcalf, Brian
, p. 603 - 606 (2007/10/03)
The design, synthesis, evaluation, and identification of a novel class of (6S,7S)-N-hydroxy-6-carboxamide-5-azaspiro[2.5]octane-7-carboxamides as the first potent and selective inhibitors of human epidermal growth factor receptor-2 (HER-2) sheddase is des
Asymmetric synthesis of conformationally constrained trans-2,3-piperidine- dicarboxylic acid derivatives
Zhuo, Jincong,Burns, David M.,Zhang, Colin,Xu, Meizhong,Weng, Lingkai,Qian, Ding-Quan,He, Chunhong,Lin, Qiyan,Li, Yun-Long,Shi, Eric,Agrios, Costas,Metcalf, Brian,Yao, Wenqing
, p. 460 - 464 (2008/01/06)
An efficient asymmetric synthesis of conformationally constrained (2S,3S)-piperidinedicarboxylic acid derivatives starting from L-aspartic acid β-tert-butyl ester and 3-chloro-2-(chloromethyl)-1-propene is described. The key steps involve N-alkylation of
SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES
-
Page/Page column 88-89, (2008/06/13)
The present invention provides compounds of the formula I: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula I are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.
